News

Clinical trial for advanced lung cancer patients at Greenslopes Private Hospital

Dec 07, 2020

Patients diagnosed with metastatic lung cancer which has spread to the brain will now have the opportunity to participate in a clinical trial within Greenslopes Private Hospital, following the launch of the Trans Tasman Radiation Oncology Group (TROG) trial OUTRUN at Icon Cancer Centre Greenslopes.

The randomised phase II trial will compare the effects of cancer drug osimertinib alone and in combination with stereotactic radiosurgery for patients with advanced EGFR mutated non-small cell lung cancer (NSCLC) which has metastasised (spread) to the brain.

Stereotactic radiosurgery is a cutting-edge technique used to treat brain metastases, including the 20-40% of NSCLC patients who develop brain metastases during the course of their disease. As part of the OUTRUN trial, up to 80 patients will be randomised to receive oral osimertinib (80mg, taken once daily) alone or following upfront stereotactic radiosurgery. Patients who are newly diagnosed or have progressed on other EGFR inhibitors may be eligible to participate.

Icon Radiation Oncologist A/Prof Mark Pinkham says that the team at Icon Greenslopes are delighted to provide advanced lung cancer patients with the opportunity to access the latest in cancer treatment.

“At Icon Greenslopes, we are always looking for new ways to deliver the best care possible for our patients. We’re proud to provide the radiation therapy component of this trial at Greenslopes whilst also leveraging access to this important study through the Icon network at South Brisbane and North Lakes sites,” A/Prof Pinkham said.

Icon Cancer Centre Greenslopes has proudly delivered cancer care within the Greenslopes Private Hospital since opening in 2017. The centre offers the latest radiation therapy techniques including stereotactic radiation therapy, an advanced technique used to precisely treat small, well-defined tumours with high doses of radiation.